Measurement of Kidney Blood Flow and Oxygen Levels by MRI

Wake Forest University (WFU)

Status: Completed

Conditions: Chronic Kidney Disease

Treatments: Drug: Furosemide; Other: Placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT01318967

IRB00010832

Details and patient eligibility

About

Comparison of renal blood flow measurements by PAH clearance and MRI

Full description

The traditional measurement of renal blood flow in ml/min involves the collection of multiple blood and urine samples after an infusion of a drug called para-aminohippurate (PAH) is given. In this study, the investigators determine the ability of MRI to estimate renal blood flow. The primary hypothesis is that renal blood flow as measured by PAH clearance is similar to renal blood flow as estimated by MRI. The measurements by PAH clearance and MRI are both performed on the same day.

Enrollment: 10 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

In this study, the investigators will enroll 16 men and women aged ≥ 18 years with Stage II - V chronic kidney disease (CKD). In addition, the investigators will enroll 4 subjects with a glomerular filtration rate (GFR) of greater than 60 ml/min who do not have any evidence of CKD.

Exclusion criteria

This study excludes those not suitable for MRI or for the interventional pharmacologic procedures.

Trial design

Primary purpose: Diagnostic

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

10 participants in 2 patient groups, including a placebo group

PAH

Placebo Comparator group

Description:

PAH measure of renal blood flow is first performed on subjects prior to administration of furosemide

Treatment:

Other: Placebo

MRI after furosemide

Active Comparator group

Description:

After the PAH measurement is complete, subjects receive 20 mg furosemide and undergo BOLD MRI to estimate renal blood flow

Treatment:

Drug: Furosemide